Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1

Interventions

Cyclophosphamide 34Doxorubicin 24fludarabine phosphate 20Vinblastine 20Nivolumab 20Dacarbazine 20Brentuximab Vedotin 20pembrolizumab 19fludarabine 18Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Filgrastim 13Melphalan 12Granulocyte Colony-Stimulating Factor 10Gemcitabine 10Bleomycin 10Tacrolimus 9Radiotherapy 9Prednisone 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Specimen Handling 8Vincristine 7Sirolimus 7Magnetic Resonance Spectroscopy 7Cyclosporine 7pegfilgrastim 6Stem Cell Transplantation 6Bendamustine Hydrochloride 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Basiliximab × 1 year × Clear all
NCT04871607 2025-12-04

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
33 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡